A bibliometric analysis of primary ovarian insufficiency from 2010 to 2020.

OBJECTIVE: This study aimed to carry out a bibliometric analysis of primary ovarian insufficiency (POI) from 2010 to 2020 and to reveal the research status and hotspots in the future. METHOD: A total of 3087 articles and reviews related to POI published from 2010 to 2020 retrieved from the Web of Science Core Collection were used for bibliometric analysis. CiteSpace and VOSviewer were adopted to analyze countries and regions, organizations, authors, journals, keywords and co-cited references. RESULTS: The number of publications about POI increased year by year. The USA produced the largest number of publications and the most influence in this field. The main research directions of POI can be roughly divided into four aspects according to the analysis of keywords and co-cited references: genetic research of POI; stem cell therapy for patients with POI; prediction of ovarian function; and fertility preservation of cancer patients. Genetic research and stem cell therapy may become research hotspots in the future. CONCLUSION: This study might be the first bibliometric study to analyze publications of POI from multiple indicators, in order to provide new opinions for the research trends and possible hotspots of POI.

Identification of the novel KIR3DL1*079 allele from a southern Chinese Han individual.

The novel KIR3DL1*079 allele differs from KIR3DL1*0150201 by a single mutation at CDS nt1119 G>T.

Identification of the novel KIR2DL2*013 allele from a southern Chinese Han individual.

The novel KIR2DL2*013 allele differs from the closest allele KIR2DL2*00302 by two non-synonymous mutations.

Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis.

OBJECTIVE: To investigate the efficacy of different electrical stimulation (ES) therapies in pain relief of patients with knee osteoarthritis (OA). METHOD: Electronic databases including MEDLINE, Embase and Cochrane Library were searched through for randomized controlled trials (RCTs) comparing any ES therapies with control interventions (sham or blank) or with each other. Bayesian network meta-analysis was used to combine both the direct and indirect evidence on treatment effectiveness. RESULTS: 27 trials and six kinds of ES therapies, including high-frequency transcutaneous electrical nerve stimulation (h-TENS), low-frequency transcutaneous electrical nerve stimulation (l-TENS), neuromuscular electrical stimulation (NMES), interferential current (IFC), pulsed electrical stimulation (PES), and noninvasive interactive neurostimulation (NIN), were included. IFC is the only significantly effective treatment in terms of both pain intensity and change pain score at last follow-up time point when compared with the control group. Meanwhile, IFC showed the greatest probability of being the best option among the six treatment methods in pain relief. These estimates barely changed in sensitivity analysis. However, the evidence of heterogeneity and the limitation in sample size of some studies could be a potential threat to the validity of results. CONCLUSION: IFC seems to be the most promising pain relief treatment for the management of knee OA. However, evidence was limited due to the heterogeneity and small number of included trials. Although the recommendation level of the other ES therapies is either uncertain (h-TENS) or not appropriate (l-TENS, NMES, PES and NIN) for pain relief, it is likely that none of the interventions is dangerous. LEVEL OF EVIDENCE: LevelⅡ, systematic review and network meta-analysis of RCTs.

A novel KIR2DL3 allele, KIR2DL3*027, identified in an individual from a southern Chinese Han population.

KIR2DL3*027 differs from the closest allele KIR2DL3*00101 by a nonsynonymous mutation in exon 7.

Characterization of the novel KIR2DL3*029 allele identified in a southern Chinese Han individual.

KIR2DL3*029 differs from the closest allele KIR2DL3*00101 by a single missense mutation at CDS nt505 C > A.

A novel KIR2DL3 allele, KIR2DL3*026, found in an individual from a southern Chinese Han population.

KIR2DL3*026 differs from the closest allele KIR2DL3*00101 by a nonsynonymous mutation in exon 4.

Full-length sequence of a novel null allele HLA-A*11:69N identified in a Chinese individual.

We describe here a novel null allele of human leukocyte antigen gene, A*11:69N, which was initially found in a blood donor from China.

Identification of the novel KIR2DL3*030 allele from a southern Chinese Han individual.

KIR2DL3*030 differs from the closest allele, KIR2DL3*00101, by a single missense mutation at CDS.

A novel KIR2DL3 variant allele, KIR2DL3*031, identified from a southern Chinese Han individual.

The novel KIR2DL3*031 allele differs from KIR2DL3*00101 by a synonymous mutation and a non-synonymous mutation.

The novel KIR2DL3*025 allele identified in an individual from a southern Chinese Han population.

The novel KIR2DL3*025 allele differs from the closest allele KIR2DL3*0010101 by a non-synonymous mutation at CDS nt280 C>A in exon 4.

A novel KIR2DL3*00110 allele identified in a southern Chinese Han individual.

KIR2DL3*00110 differs from KIR2DL3*00101 by a single silent mutation at coding sequence (CDS) nt618 A>C in exon 5.

Description of the novel HLA-DPB1*166:01 allele identified by sequence-based typing.

The novel HLA-DPB1*166:01 allele differs from the closest allele DPB1*152:01 by a single missense mutation at CDS nt 315G>A in exon 2.

Effectiveness of continuous and pulsed ultrasound for the management of knee osteoarthritis: a systematic review and network meta-analysis.

BACKGROUND: To investigate the efficacy of continuous and pulsed ultrasound (US) in the management of knee osteoarthritis (OA). DESIGN: This systematic review and network meta-analysis covered 12 trials in total. Electronic databases including MEDLINE, Embase and Cochrane Library were searched through to identify randomized controlled trials comparing the two modes of US with control interventions (sham or blank) or with each other. Bayesian network meta-analysis was used to integrate both the direct and indirect evidences on treatment effectiveness. RESULTS: Pulsed US (PUS) is more effective in both pain relief and function improvement when compared with the control group; but for continuous US (CUS), there is only a significant difference in pain relief in comparison with the control group. In addition, no matter in terms of pain intensity or function at the last follow-up time point, PUS always exhibited a greater probability of being the preferred mode. However, the evidence of heterogeneity and the limitation in sample size of some studies could be a potential threat to the validity of results. CONCLUSIONS: Our findings indicated that PUS, with a greater probability of being the preferred mode, is more effective in both pain relief and function improvement when compared with the control group. However, CUS could only be considered as a pain relief treatment in the management of knee OA. The findings also confirmed that none of these modes is dangerous. LEVEL OF EVIDENCE: Level II, systematic review and network meta-analysis of randomized controlled trials.

A novel MICA allele, MICA*069, identified by sequence-based typing in a Chinese individual.

MICA*069 differs from MICA*010:01 by one nucleotide at position 1118 within exon 6.

Characterization of the novel HLA-DPB1*140:01 allele identified by sequence-based typing.

The novel HLA-DPB1*140:01 variant allele differs from the closest allele DPB1*05:01:01 by single nucleotide change at genomic nt 4898G>C in exon 2.

MICA*066, a novel major histocompatibility complex class I-related chain A allele found by high-resolution HLA-matching tests for hematopoietic stem cell transplantation.

MICA*066, a novel MICA allele identified in HLA/MICA typing of a unrelated donor hematopoietic stem cell transplantation donor-patient pair.

Identification of the novel HLA-B allele B*57:29 by cloning and sequencing in a Chinese individual.

HLA-B plays an important role in unrelated donor hematopoietic stem cell transplantation.

Identification of a novel HLA-C*01 variant allele, C*01:46.

A novel HLA-C*01 variant allele differs from the closest allele C*01:02:01 by single nucleotide change at coding sequence nt 316 C>T (codon 82 CGC>TGC) in exon 2, which causes an amino acid change Arg82Cys.

A novel HLA-C*01 variant allele, HLA-C*01:38.

The novel HLA-C*01:38 variant allele differs from the closest allele C*01:02:01 by a single nucleotide change at coding sequence (CDS) nt 430 G>A (codon 120 GGC>AGC) in exon 3, which causes an amino acid change Gly120Ser.